AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.

(RTTNews) - AbbVie (ABBV) and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology. The ...

EvolveImmune CEO Stephen Bloch said: "This collaboration with AbbVie, a global leader in oncology, offers tremendous validation of the EVOLVE platform and the dedicated and creative work of the ...

If approved, the drug would join three other oncology drugs in the AbbVie pipeline. The company also has several investigational cancer treatments for blood and solid tumors. "We are focusing on ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...

The company's immunology franchise ... hold for future growth? AbbVie's pipeline is rich with potential, particularly in neuroscience and oncology, which could drive substantial future growth ...

Welcome to the AbbVie third quarter 2024 earnings conference call. [Operator instructions] I would now like to introduce Ms.

AbbVie's strategic acquisitions bolster its pipeline in oncology and neuroscience. Financial performance reflects strong net revenue growth and substantial cash flow generation. Recent FDA approvals ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...